Pemoline-associated hepatic injury

Area of Science:

• Hepatology
• Pharmacology
• Toxicology

Background:

• Pemoline, a stimulant medication, has been associated with adverse hepatic events.
• Understanding the risk factors and characteristics of pemoline-induced liver injury (APELI) is crucial for patient safety.

Observation:

• A review of 100 cases of hepatic injury linked to pemoline identified 43 suitable for analysis.
• The majority of affected patients were pediatric, with 80% under 12 years old and predominantly male.
• Liver injury onset varied widely, from one week to over a year after pemoline initiation.

Findings:

• The hepatic injury was consistently hepatocellular, indicated by elevated aminotransferase levels.
• One patient experienced fatal massive hepatic necrosis, confirming the severity of the injury.
• The mechanism of injury was deemed idiosyncratic, likely stemming from metabolic processes rather than an immunologic response.

Implications:

• This highlights the significant hepatotoxic potential of pemoline, particularly in pediatric populations.
• Clinicians should be aware of the risk of severe, idiosyncratic liver injury when prescribing pemoline.
• Further research into the metabolic pathways underlying pemoline hepatotoxicity may inform safer drug development.